Detalhe da pesquisa
1.
Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Plasma Ceramide Levels.
Am J Cardiol
; 128: 163-167, 2020 08 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32650914
2.
Characteristics and Outcomes of Patients Treated With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (The Mayo Clinic Experience).
Am J Cardiol
; 124(11): 1669-1673, 2019 12 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31740018